ENLIVEX LTD
ENLVNASDAQTrading Snapshot
- Day Range
- $2.55 – $2.77
- 52-Week Range
- $2.22 – $434.40
- Volume (shares)
- 35,897
- Avg Volume (shares)
- —
- Shares Outstanding
- 24.5M
- Next Earnings
- 2026-11-12
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- 0.0
- P/S Ratio
- —
- EPS (TTM)
- $149.76
- Dividend Yield
- —
- Dilution (1yr)
- +120.1%
ENLIVEX LTD
ENLV
StockOtter · stockotter.spaceAbout ENLIVEX LTD
Enlivex Therapeutics Ltd., established in 2005 and based in Nes Ziona, Israel, operates as a clinical-stage biotechnology firm dedicated to macrophage reprogramming immunotherapy. The company is currently advancing Allocetra, its flagship cell-based therapeutic. This treatment is undergoing Phase II clinical evaluation for its effectiveness in addressing organ dysfunction and failure that arises from sepsis. Additionally, Allocetra is being investigated in preclinical studies for its potential application in solid tumor therapy.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Analyst Ratings
ⓘLatest News & Updates
Enlivex Announces Randomization of 135 Patients in Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
• 135 patients, out of a total planned 182, have been randomized and were administered the first injection of AllocetraTM; enrollment actively ongoing at clinical sites in the United States and in Europe • Topl
Enlivex Announces Receipt of Delisting Notice from Nasdaq; Intends to Appeal
Nes-Ziona, Israel, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV) ("Enlivex" or the "Company"), a quality longevity company powered by a prediction markets treasury, today announced receipt of a delisting
Enlivex Announces 1-for-16 Reverse Share Split to be Effective October 27, 2026
Nes-Ziona, Israel, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV) ("Enlivex" or the "Company"), a quality longevity company powered by a prediction markets treasury, today announced a 1-for-16 reverse spli
Enlivex Announces Cost Reduction Plan to Focus Resources on Phase 2b Trial of Allocetra™ in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
Nes-Ziona, Israel, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV) ("Enlivex" or the "Company"), a quality longevity company powered by a prediction markets treasury, today announced a cost reduction plan,
Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Shares Shorted: Short Interest Down 59.8% in September
Enlivex Therapeutics Ltd. (NASDAQ: ENLV - Get Free Report) was the target of a significant drop in short interest in September. As of September 15th, there was short interest totaling 48,204 shares, a drop of 59.8% from
Enlivex Announces Termination of Previously-Announced Financing Payable in RAIN Tokens
Nes-Ziona, Israel, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd.